MEDIA RELEASE NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN New USD 2.0 billion multi-currency revolving credit ...

After Delpharm bought the Boucherville plant in 2022, Sandoz signed an exclusive partnership with the company to maintain its ...

Avecho (ASX:AVE) has received a US$3 million (A$4.7 million) payment from pharma heavyweight Sandoz in exchange for the ...

Sandoz completed its long-heralded separation from Novartis on schedule this morning, with its shares trading at CHF 24 on the SIX Swiss Exchange. That valued the newly independent company at CHF ...

Richard Saynor wants to transform Sandoz Group AG into a world champion in copying leading-edge drugs, including anti-obesity and biological treatments, with the goal of bringing them to the masses.

Sandoz's 2024 revenue grew 4%, with a core EBITDA margin of 20.1%, generating $622M in free cash flow, or $1.45/share. Click ...

Recently, pharmaphorum spoke with Sebastian Katz, chief strategy officer of specialty healthcare company Stein Holding Group (SteinCares), to discuss the announcement of its licensing agreement ...

Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first financial year as an independent company. After completing its spin-off from ...

After getting its hands on a massive Quebecois manufacturing plant from Sandoz in 2022, French CDMO Delpharm is making good ...

Sandoz is one of the largest off-patent pharmaceutical manufacturers in the world. It generates roughly 75% of sales from generic drugs with the remainder from biosimilars and has a significant ...